ARVN News and Press, Arvinas Inc. From 05/08/19

Arvinas (NASDAQ: ARVN ): Q1 GAAP EPS of -$0.46 in-line. More news on: Arvinas, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

NEW HAVEN, Conn., May 08, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies that degrades disease-causing proteins, today reported financial results for the first quarter of 2019 and provided a corporate update. “T...

Sector Technicals Last week, the XBI (SPDR Biotech ETF) and IBB (iShares Nasdaq Biotechnology ETF) fell 4.16% and 3.38%, respectively. When markets have a tough week, take advantage of this opportunity to scan for stocks that are swimming upstream against the tide. Data by YCharts ...

NEW HAVEN, Conn., April 02, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies that degrades disease-causing proteins, announced that two members of the senior leadership team were appointed to expanded roles at the company.&...

Shares of Arvinas (ARVN) are currently trading at a 10% discount to the IPO price point of $16 , which took place in September of 2018. So far, in 2019, the stock saw an impressive 75% run-up before shares essentially pulled back to square one. This one caught my eye when it came to public ...

Arvinas (NASDAQ: ARVN ): Q4 GAAP EPS of -$0.52 beats by $0.08 . More news on: Arvinas Holding Company, LLC, Earnings news and commentary, Healthcare stocks news, Read more ...

NEW HAVEN, Conn., March 26, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies that degrade disease-causing proteins, today reported financial results for the fourth quarter and full year ended December 31, 2018 and...

NEW HAVEN, Conn., March 25, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies that degrade disease-causing proteins, today announced the initiation of patient dosing in its Phase 1 clinical trial of ARV-110, the company ...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The increasingly hot market for online video delivery is set to take another sharp ...